Kovack Advisors’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Kovack Advisors’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,000	Closed	-$6K	–	775
2022 Q1	$6K	Buy	+10,000	New	+$6K	﹤0.01%	719
2021 Q3	–	Sell	-25,000	Closed	-$37K	–	775
2021 Q2	$37K	Buy	+25,000	New	+$37K	﹤0.01%	663
2014 Q1	–	Sell	-11,978	Closed	-$45K	–	97
2013 Q4	$45K	Sell	11,978 -738	-6%	-$2.86K	0.24%	57
2013 Q3	$43K	Sell	12,716 -4,229	-25%	-$14.7K	0.22%	53
2013 Q2	$57K	Buy	+16,945	New	+$61.4K	0.34%	45

Other funds holding NWBO

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

MSAM

Moloney Securities Asset Management Manchester, Missouri $840M AUM 18.11% 1-Year Est. Return

OCG

Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return

WJWM

Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return

GWI

Grace & White Inc Ny, New York $632M AUM 34.34% 1-Year Est. Return

AIP

Almanack Investment Partners Wayne, Pennsylvania $785M AUM 34.37% 1-Year Est. Return

LDB

Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return

Kovack Advisors's NWBO Position: Q2 2022 in Review

Kovack Advisors sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2022, closing a stake of 10,000 shares — an estimated $6K sold.

Kovack Advisors first reported a position in NWBO in Q2 2013 and held it in 5 quarters. The position peaked at $57K in Q2 2013. 14 funds tracked by Wall St. Rank hold NWBO as of Q2 2022.

Kovack Advisors reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2022 after selling out during the quarter.
Kovack Advisors sold 10,000 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2022, an estimated $6K.
Kovack Advisors first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2013 and held it in 5 quarters.
Kovack Advisors's Northwest Biotherapeutics, Inc. Common stock position peaked at $57K in Q2 2013.
14 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2022.

Based on Kovack Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.